We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Bioperfectus SARS-CoV-2 Antigen Rapid Test Kit with High Sensitivity and Specificity Assists in Fight against COVID-19 Pandemic

By HospiMedica International staff writers
Posted on 12 Mar 2021
Jiangsu Bioperfectus Technologies Co., Ltd.’s (Shanghai, China) Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit with clinically proven high sensitivity and specificity is playing an important role in COVID-19 diagnostics as a fast and cost-efficient antigen test.

While the reverse transcription real-time polymerase chain reaction (RT-PCR) assay, which is a nucleic acid amplification test (NAAT), remains the “gold standard” for COVID-19 diagnosis, rapid antigen tests, which detect the presence of viral proteins (antigens) are proving to be a faster and cheaper way for communities to detect ongoing infection. Despite their growing demand, there has been a shortage of COVID-19 rapid antigen tests in Europe due to the heavy reliance of EU countries on rapid antigen tests as a surplus testing option through the next phase of the pandemic, slow pace of vaccination, and a comparatively weak supply chain.

Image: Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit (Photo courtesy of Jiangsu Bioperfectus Technologies Co., Ltd.)
Image: Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit (Photo courtesy of Jiangsu Bioperfectus Technologies Co., Ltd.)

Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit with its clinical proven accuracy is helping healthcare workers to quickly find out whether someone is currently at risk of spreading the disease, which will effectively curb the further spread of the virus. Bioperfectus COVID-19 rapid antigen test has been clinically proven to have high sensitivity of 96.7% and specificity of 97.9% by several institutes worldwide. Additionally, in a recent evaluation performed by the UK Department of Health and Social Care, Bioperfectus COVID-19 rapid antigen test showed no drop off in sensitivity when compared with the wild type with respect to the following variants - VOC1 Kent, UK, B.1.1.7 and VOC2 South Africa, B.1.351.

Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test offers nasal, nasopharyngeal and oropharyngeal swab in both sterile tube and sterile peel-down pouch packages to meet the varied testing demands in different clinical laboratories across the world. Bioperfectus COVID-19 rapid antigen test also offers additional advantages such as fast results within 15 minutes, easy three-step use, swab with optional protective jacket to avoid biohazard, quality control for reliable results, and inclusion of all necessary components in the kit.

Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Monitor Cart
Tryten S5
New
Mini C-arm Imaging System
Fluoroscan InSight FD

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles